Forge Therapeutics is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry to target metalloproteins. Forge has developed a fundamentally new approach for the discovery of metalloprotein inhibitors by focusing first on the metal in the enzyme active site.
Location: United States, California, San Diego
Employees: 11-50
Total raised: $26.1M
Founded date: 2015
Investors 3
| Date | Name | Website |
| - | Tech Coast... | techcoasta... |
| - | CARB-X | carb-x.org |
| - | MP Healthc... | mp-healthc... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.01.2019 | - | $11.1M | - |
| 16.05.2017 | Series A | $15M | - |
Mentions in press and media 10
| Date | Title | Description |
| 25.04.2019 | After Biogen exit, Mitsubishi Tanabe Pharma links up with Salix to develop amiselimod; Two drug developers set up antibiotic collaboration | → About two years after Biogen $BIIB walked away from Mitsubishi Tanabe Pharma‘s MT-1303 (amiselimod), the Japanese drugmaker has joined forces with Bausch Health’s Salix Pharmaceuticals to develop the late-stage oral comp... |
| 03.01.2019 | Forge Therapeutics Gets $11.1M | San Diego-based Forge Therapeutics, a biotechnology startup which is developing antibiotics to treat lung infections, has received $11.M in funding commitments from CARB-X, a public-private investor funding projects that target antibiotic r... |
| 16.05.2017 | Forge Therapeutics Raises $15M | - |
| 16.05.2017 | Forge Therapeutics Names Board | San Diego-based antibiotics developer Forge Therapeutics announced oday that it has named its board of directors, adding Mario Polywka (COO of Evotec AG), John Schmid, (former CFO of Trius and Auspex Pharmaceuticals), Stephen Worland (Presi... |
| 26.04.2017 | Term Sheet — Wednesday, April 26 | ET CETERA Good morning! This the third-largest ever “ed tech” deal, aside from German publishing giant Bertelsmann’s $230 million stake in HotChalk and a $200 million fundraising by TutorGroup, an Alibaba-backed English tutoring startup. Th... |
| 25.04.2017 | Forge Therapeutics Raises $15M Series A Financing to Develop First Novel Gram-Negative Antibiotic In Decades. | - |
| 25.04.2017 | Forge Therapeutics Gets $15M | San Diego-based Forge Therapeutics, a biotechnology startup developing antibiotics, said on Tuesday that it has raised $15M in a Series A funding. The funding was led by MagnaSci Ventures, along with Evotec AG, Alexandria Venture Investment... |
| 25.04.2017 | Forge Therapeutics Raises $15M in Series A Funding | Forge Therapeutics, Inc., a San Diego, CA-based biotechnology company discovering antibiotics using an innovative drug discovery platform, closed a $15M Series A financing. The round was led by MagnaSci Ventures, with participation from Evo... |
| 30.03.2017 | CARB-X dishes out $48M in grants to antimicrobial startups | Launched in mid-2016, CARB-X stands for Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator. It comes in response to the growing threat of drug-resistant infections — and the concerning lack of late-stage antibacterial dru... |
| - | CARB-X dishes out $48M in grants to antimicrobial startups | CARB-X is making it rain. The international antimicrobial consortium today announced grants totaling $48 million, spread across 11 companies in the U.S. and U.K. Launched in mid-2016, CARB-X stands for Combating Antibiotic Resistant Bacteri... |